Breaking News Instant updates and real-time market news.

APPS

Digital Turbine

$3.66

-0.11 (-2.92%)

, COUP

Coupa Software

$102.34

-6.92 (-6.33%)

18:51
06/03/19
06/03
18:51
06/03/19
18:51

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Digital Turbine (APPS) up 7.3%... Coupa Software (COUP) up 4.4%... Caleres (CAL) up 1.1%... ALSO HIGHER: Continental Resources (CLR) up 3.1% after announcing $1B buyback... Netlix (NFLX) up 0.5% after being upgraded to Buy at Loop Capital... DOWN AFTER EARNINGS: Box (BOX) down 13.0%... ALSO LOWER: Sientra (SIEN) down 7.0% after equity offering... i3 Verticals (IIIV) down 2.7% after equity offering... Ventas (VTR) down 2.0% after equity offering... Movers as of 18:30ET.

APPS

Digital Turbine

$3.66

-0.11 (-2.92%)

COUP

Coupa Software

$102.34

-6.92 (-6.33%)

CAL

Caleres

$19.43

0.57 (3.02%)

CLR

Continental Resources

$35.01

(0.00%)

NFLX

Netflix

$336.86

-6.41 (-1.87%)

BOX

Box

$17.95

-0.54 (-2.92%)

SIEN

Sientra

$5.45

-0.37 (-6.36%)

IIIV

i3 Verticals

$24.67

-0.91 (-3.56%)

VTR

Ventas

$64.14

-0.17 (-0.26%)

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 11

    Jun

  • 14

    Jun

  • 19

    Jun

  • 25

    Jun

  • 13

    Nov

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

APPS Digital Turbine
$3.66

-0.11 (-2.92%)

02/26/19
RILY
02/26/19
NO CHANGE
Target $4
RILY
Buy
Digital Turbine price target raised to $4 from $2.90 at B. Riley FBR
B. Riley FBR analyst Sameet Sinha raised his price target for Digital Turbine to $4 saying the company's domestic revenue-per-device has four-times appreciation potential. The analyst keeps a Buy rating on the shares.
01/03/19
ROTH
01/03/19
NO CHANGE
Target $3
ROTH
Buy
Apple weakness could spill over into Digital Turbine, says Roth Capital
Roth Capital analyst Darren Aftahi says weakness from Apple's (AAPL) negative pre-announcement, citing primarily emerging market weakness and fewer iPhone upgrades, could spill over into Digital Turbine (APPS). The analyst would be a buyer on any material weakness given Digital Turbine has no handset exposure to China and its exposure is to the Android based platform, where handsets tend to skew lower on ASP, in general. Apple weakness could create buying opportunity, he contends. Aftahi reiterates a Buy rating and $3 price target on Digital Turbine's shares.
03/26/19
RILY
03/26/19
NO CHANGE
Target $4
RILY
Buy
Digital Turbine selloff yesterday a buying opportunity, says B. Riley FBR
B. Riley FBR analyst Sameet Sinha views the selloff yesterday in shares of Digital Turbine (APPS) on Google's (GOOG, GOOGL) potential changes to Chrome as a buying opportunity. The analyst believes the changes should have a minimal impact on Digital Turbine and keeps a Buy rating on the shares with a $4 price target. The stock closed yesterday down 14% to $3.09.
03/27/19
ROTH
03/27/19
NO CHANGE
Target $4.25
ROTH
Buy
Digital Turbine selloff creates buying opportunity, says Roth Capital
Roth Capital analyst Darren Aftahi believes Digital Turbine's (APPS) shares were weak on chatter about changes Google (GOOG; GOOGL) could make to its Chrome browser and third-party ad-targeting restrictions. The analyst argues that the company was lumped into this basket, when in fact about 85% of its revenue still comes from dynamic pre-load with the remaining 15% from new services, which to his knowledge have little if most likely any exposure to Google. Aftahi would be "accumulating on unnecessary weakness." He reiterates a Buy rating and a $4.25 price target on Digital Turbine's shares.
COUP Coupa Software
$102.34

-6.92 (-6.33%)

03/13/19
LOOP
03/13/19
NO CHANGE
Target $105
LOOP
Buy
Coupa Software price target raised to $105 from $85 at Loop Capital
Loop Capital analyst Joseph Vafi raised his price target on Coupa Software to $105 and kept his Buy rating after its Analyst Day presentation, saying the company may be on the way to becoming "the Venmo of procurement". The analyst notes the rising cumulative customer spend at $1.1T on the company's platform exiting 2019 and its building momentum, stating that Coupa Software has "figured out a dual market sales model, targeting both the enterprise and the mid market simultaneously" as evidenced in its SG&A leverage. Vafi adds that he is also very "enthusiastic" about its Coupa Pay as the company "exploits its positioning in procurement to migrate into the payment function."
05/13/19
BOFA
05/13/19
INITIATION
Target $120
BOFA
Buy
Coupa Software initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Brad Sills initiated Coupa Software with a Buy and $120 price target telling investors the company is gaining share in the applications market given its leading cloud market position, ease of deployment/use, breadth of offering, and large network of suppliers and large number of data sets.
03/13/19
CANT
03/13/19
NO CHANGE
Target $110
CANT
Overweight
Coupa Software continues on path to $1B in sales, says Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi views Coupa Software's analyst day as successful, saying the company laid out its continued path to $1B in revenues, "which expands well beyond its single-platform competitive advantage." The net result should be a financial model with 30%-plus growth, while the company maintains efficiencies and drives leverage, Foresi tells investors in a research note. He keeps an Overweight rating on the shares with a $110 price target.
04/30/19
KEYB
04/30/19
INITIATION
Target $123
KEYB
Overweight
Coupa Software initiated with an Overweight at KeyBanc
KeyBanc analyst Brent Bracelin started coverage of Coupa Software with an Overweight rating and $123 price target, based on new product potential, international expansion, Federal, and a unique data asset that is in the early stages of monetization. The analyst believes new products in 2019 that "monetize an underappreciated data asset" and new B2B payment offerings could become game changers for the company and help accelerate the path to $1B in revenue.
CAL Caleres
$19.43

0.57 (3.02%)

04/22/19
NEED
04/22/19
UPGRADE
NEED
Buy
Caleres upgraded to Buy from Hold at Needham
04/22/19
NEED
04/22/19
UPGRADE
Target $32
NEED
Buy
Caleres upgraded to Buy from Hold at Needham
Needham analyst Rick Patel upgraded Caleres to Buy from Hold with a price target of $32, saying that his recent meeting with its CEO and CFO have given him an added confidence about the FY19 EPS guidance being "achievable and likely beatable". The analyst notes that the stock has recently underperformed the SPDR retail ETF (XRT) due to investor concerns "about Famous comps and lower sales at Allen Edmonds", but believes that the company has the "material drivers" to produce positive comps and expanding margins this year. Patel adds that while reduced promotional activity could weigh on sales in the near term, this should protect the brand longer term.
04/22/19
04/22/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. IPG Photonics (IPGP) upgraded to Buy from Neutral at BofA/Merrill. 2. Caleres (CAL) upgraded to Buy from Hold at Needham with analyst Rick Patel saying that his recent meeting with its CEO and CFO have given him an added confidence about the FY19 EPS guidance being "achievable and likely beatable." 3. Viavi (VIAV) upgraded to Neutral from Underweight at JPMorgan with analyst Samik Chatterjee saying the "buildup of industry tailwinds" in the form of 5G network deployments as well as fiber densification and adoption of 3D Sensing should drive medium-term growth above expectations. 4. Alcoa (AA) upgraded to Buy from Hold at Gabelli. 5. Lam Research (LRCX) upgraded to Buy from Neutral at B. Riley FBR with analyst Craig Ellis saying he sees "increasingly visible recent signs" of a cyclical trough in Q1. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
04/10/19
UPGRADE
Target $32

Buy
Caleres upgraded to Buy at Loop Capital after management meetings
As previously reported, Loop Capital analyst Laura Champine upgraded Caleres to Buy from Hold and raised her price target to $32 from $26 after holding "management meetings that clarified and expanded on near- and long-term company strategy." The analyst also maintains her revenue forecasts to reflect the "choppy, weather-driven sales trends" but boosts her FY19 EPS estimate by 10c to $2.55 on "more bullish margin estimates".
CLR Continental Resources
$35.01

(0.00%)

04/23/19
IFSG
04/23/19
DOWNGRADE
IFSG
Market Perform
Continental Resources downgraded to Market Perform at IFS Securities
01/29/19
01/29/19
INITIATION

Mizuho initiates seven 'exciting' E&P stocks
Mizuho analyst Paul Sankey expanded his coverage of the E&P, or exploration and production, sector with the initiation of seven U.S.-focused, liquids-weighted E&Ps. Sankey initiated Concho Resources (CXO), Continental Resources (CLR), and Diamondback Energy (FANG) with Buy ratings, and Cimarex Energy Company (XEC), Encana Corporation (ECA), Parsley Energy (PE), and WPX Energy (WPX) with Neutral ratings. The analyst views each of these names as quality operators at varying stages in the transition to "Renaissance E&P." He believes "sustainable cash return growth is the key to making E&Ps competitive, not just relative to their history, but to the broader market," and sees his three Buy-rated names as the furthest along this process.
02/12/19
KEYB
02/12/19
INITIATION
Target $52
KEYB
Overweight
Continental Resources initiated with an Overweight at KeyBanc
KeyBanc analyst Leo Mariani started Continental Resources with an Overweight rating and $52 price target. The analyst likes the company's "consistent" free cash flow generation and its "likely beta reaction" to a continued oil price recovery.
03/04/19
SBSH
03/04/19
NO CHANGE
Target $55
SBSH
Buy
Continental Resources price target lowered to $55 from $65 at Citi
Citi analyst Robert Morris lowered his price target for Continental Resources to $55 citing the company's slower growth outlook post its Q4 results. He keeps a Buy rating on the shares.
NFLX Netflix
$336.86

-6.41 (-1.87%)

06/03/19
LOOP
06/03/19
UPGRADE
Target $425
LOOP
Buy
Netflix upgraded to Buy from Hold at Loop Capital
Loop Capital analyst Alan Gould upgraded Netflix to Buy from Hold and raised his price target for the shares to $425 from $395.
04/30/19
JPMS
04/30/19
NO CHANGE
Target $1310
JPMS
Overweight
Alphabet sub-20% sales growth to bring share pressure, says JPMorgan
JPMorgan analyst Doug Anmuth expects Alphabet (GOOGL) shares to be under pressure in the near-term given the company's sub-20% revenue growth in Q1 and downward earnings revisions. The exact drivers of Alphabet's slowing sales are unclear, and frustration around the company's lack of transparency will only increase, Anmuth tells investors in a post-earnings research note. The analyst, however, points out that Alphabet has maintained 20%-plus growth for a very long time, off a large base. He maintains an Overweight rating on the stock with a $1,310 price target but prefers shares of Facebook (FB), Amazon.com (AMZN) and Netflix (NFLX) to Alphabet.
05/07/19
BMOC
05/07/19
NO CHANGE
Target $170
BMOC
Outperform
Disney price target raised to $170 from $140 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Disney (DIS) to $170 and kept his Outperform rating ahead of its Q2 results, saying he expects an "upbeat quarter" and positive commentary around June quarter's main events of Endgame box office and the first Edge of Galaxy opening. The analyst also believes that the company will join Netflix (NFLX) and Amazon (AMZN) at the helm of global streaming while noting that its Star Wars themed lands its theme parks and the launch of Disney+ will materialize as catalysts for this year.
05/13/19
PIPR
05/13/19
NO CHANGE
Target $440
PIPR
Overweight
Piper survey shows limited risk to Netflix from Disney streaming service
Piper Jaffray asked 1,536 U.S. Netflix (NFLX) subscribers if they would subscribe to both Disney's (DIS) new streaming service and Netflix, only Netflix or only Disney+, analyst Michael Olson tells investors in a research note. Piper indicated that the Disney+ price point is $7 per month, which it believes will prove to be only an introductory price. The results show that 73% of U.S. Netflix subscribers do not expect to subscribe to Disney+, 20% expect to subscribe to both services, and only 7% indicated that they will cancel Netflix and subscribe to Disney+, Olson tells investors in a research note. The results suggest Netflix's risk of share loss is limited to a small percentage of its base, concludes the analyst. As such, he expects Netflix to continue to "capture a significant portion of the tidal wave of traditional content dollars that are migrating to streaming." Olson maintains an Overweight rating on Netflix shares with a $440 price target. The stock closed Friday down $1.71 to $361.04.
BOX Box
$17.95

-0.54 (-2.92%)

02/28/19
RSBL
02/28/19
DOWNGRADE
Target $21
RSBL
Neutral
Rosenblatt downgrades Box to Neutral after 'very disappointing quarter'
As previously reported, Rosenblatt analyst Marshall Senk downgraded Box to Neutral from Buy following what he called a "very disappointing quarter," noting that the company missed on all of its top-line metrics. The bottom line is that management failed to meet the expectations they set and his confidence has been diminished, Senk stated. His view is that the company is going to take at least another two, and maybe more, quarters to show improvement, Senk added. He cut his Q1 and FY20 estimates and lowered his price target on Box shares to $21 from $27.
04/05/19
WELS
04/05/19
NO CHANGE
Target $27
WELS
Outperform
Wells Fargo 'cautiously optimistic' on Box after meetings with CEO
Wells Fargo analyst Philip Winslow said he came away from investor meetings he hosted with Box CEO Aaron Levie "cautiously optimistic" on Box's ability to improve execution on the company's go-to-market strategy and the potential benefits of its product portfolio changes and additions. Winslow, who thinks "reaccelerating growth is still on the table - just not in the timeframe originally forecasted," keeps an Outperform rating and $27 price target on Box shares.
02/28/19
DADA
02/28/19
NO CHANGE
Target $25
DADA
Buy
Box price target lowered to $25 from $30 at DA Davidson
DA Davidson analyst Rishi Jaluria lowered his price target on Box to $25 after its "rough" Q4 results, stating that its billings came in well below consensus. The analyst also notes that the disappointing results and guidance were driven by weakness in EMEA, longer sales cycles pressuring 7-figure deals, and a reduction of spending by one of the company's big customers. Jaluria keeps his Buy rating on Box however, stating that based on the "disappointing quarter, reset to numbers, and potentially growing investor unrest", the company may emerge as a potential private equity takeout target.
02/28/19
02/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Booking Holdings (BKNG) downgraded to Neutral from Overweight at Atlantic Equities and Piper Jaffray, as well as to Perform from Outperform at Oppenheimer. 2. Box (BOX) downgraded to Sector Weight from Overweight at KeyBanc and to Neutral from Buy at Rosenblatt. 3. HP Inc. (HPQ) double downgraded to Underperform from Buy at BofA/Merrill with analyst Wamsi Mohan citing the company's Q1 report last night. 4. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank. 5. Dollar General (DG) and Big Lots (BIG) were downgraded to Hold from Buy at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SIEN Sientra
$5.45

-0.37 (-6.36%)

04/23/19
CHLM
04/23/19
NO CHANGE
Target $23
CHLM
Buy
Craig-Hallum bullish on Sientra after FDA news
Craig-Hallum analyst Alexander Nowak notes that shares of Sientra finished up 9% on Monday after FDA approved four new styles of the company's silicone gel breast implants. It appears the approval is for two textured implants and two smooth implants, he adds. The analyst points out that the market has been concerned that FDA could remove all textured implants from the market, and views this as the de-risking event to kick-off a turnaround for the stock. Once FDA concerns are fully in the rearview, investors can redirect attention back to taking market share with a superior implant, he contends. Nowak reiterates a Buy rating and a $23 price target on the shares.
03/26/19
SPHN
03/26/19
NO CHANGE
Target $26
SPHN
Overweight
Sientra implants not at risk of FDA temporary moratorium or ban, says Stephens
After attending the first day of the FDA's Plastic Surgery Devices Advisory Committee Meeting, Stephens analyst Chris Cooley said it is his view that Sientra's textured silicone gel implants are not at risk of an FDA temporary moratorium or ban. The panel's conclusion that all textured implants are not equal also makes a category ban on textured implants unlikely, Cooley added. He remains comfortable with his "modestly above consensus" revenue estimates for Sientra and reiterates an Overweight rating and $26 price target on the stock.
03/26/19
CHLM
03/26/19
NO CHANGE
Target $23
CHLM
Buy
Any weakness in Sientra shares should be short-term, says Craig-Hallum
Following day 1 of the FDA panel meeting, Craig-Hallum analyst Alexander Nowak expects the agency to issue new rules around labeling and establish a universal post-marketing study. The analyst believe it is still possible, but less likely that FDA will remove all textured implants from the market. Nowak wrapped-up day 1 of the meeting with continued confidence that the panel will be a nonevent for Sientra. The more likely impact is near-term sluggishness in the breast implant market, which Sientra alluded to on its Q4 call, he adds, arguing that any weakness in the shares will be short-term. The analyst reiterates a Buy rating and $23 price target on the shares.
04/22/19
CHLM
04/22/19
NO CHANGE
Target $23
CHLM
Buy
Sientra approval may indicate FDA 'comfortable' with data, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak says Sientra has gained 6% after the company gained FDA approval for four new styles of round breast implants, adding that he has not seen the product codes before, but they could be for Sientra's new line of extra-large, ultra-high profile breast implants. Nowak says FDA approval for these new implants -- two types of smooth implants and two types of textured implants -- could be viewed as more of a positive than normally, as there has been discussion if textured implants would be removed from the market and says the market may read into this that FDA is comfortable with Sientra's safety data. He maintains a Buy rating and $23 price target.
IIIV i3 Verticals
$24.67

-0.91 (-3.56%)

07/16/18
RAJA
07/16/18
INITIATION
Target $19
RAJA
Outperform
i3 Verticals initiated with an Outperform at Raymond James
Raymond James analyst John Davis initiated i3 Verticals with an Outperform rating and $19 price target.
03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
10/24/18
DADA
10/24/18
INITIATION
Target $26
DADA
Buy
i3 Verticals initiated with a Buy at DA Davidson
DA Davidson analyst Peter Heckmann initiated i3 Verticals with a Buy rating and a price target of $26, saying the company is "positioned to generate strong growth in revenue and earnings by further penetrating the market for integrated payment and software solutions". The analyst expects i3 Verticals to continue to engage in "accretive acquisitions" and also generate organic growth. Heckmann is also positive on the company's management bringing a "proven track record of building profitable enterprises in the payments space through acquisitions" along with its solid balance sheet and growing free cash flows.
12/11/18
BTIG
12/11/18
INITIATION
Target $27
BTIG
Buy
i3 Verticals initiated with a Buy at BTIG
BTIG analyst Mark Palmer initiated i3 Verticals with a Buy rating and a price target of $27. The analyst cites the company's focus on "attractive payment verticals" in its acquisitions since 2012 within the "large and growing" markets of education, non-profit, public sector, property management and healthcare. Palmer sees i3 Verticals faced with less competition in these markets and expects it to continue generating business wins based on its "ability to tailor embedded payment capabilities to the market-specific needs of its clients".
VTR Ventas
$64.14

-0.17 (-0.26%)

12/10/18
SCOT
12/10/18
INITIATION
Target $66
SCOT
Sector Perform
Ventas initiated with a Sector Perform at Scotiabank
Scotiabank analyst Nicholas Yuico initiated Ventas with a Sector Perform and $66 price target.
03/28/19
MSCO
03/28/19
INITIATION
Target $61
MSCO
Equal Weight
Ventas initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Vikram Malhotra initiated Ventas (VTR) with an Equal Weight rating and $61 price target, stating that given his forecasts for occupancy and rate growth for REIT markets, he expects Welltower (WELL) and HCP (HCP) markets to see the highest level of revenue growth and for Ventas and New Senior Investment (SNR) to see relatively lower revenue growth this year.
04/30/19
RAJA
04/30/19
UPGRADE
RAJA
Market Perform
Ventas upgraded to Market Perform from Underperform at Raymond James
04/29/19
MUFG
04/29/19
NO CHANGE
Target $61
MUFG
Neutral
Ventas price target raised to $61 at MUFG after Q1 earnings beat
MUFG analyst Karin Ford nudged her price target on Ventas to $61 from $60 after its "slightly better than expected" Q1 results, saying her outlook for senior housing prospects of the REIT have improved. The analyst cites the company's positive trends in its occupancy and absorption metrics, and also sees its multiple of an 8% premium to net asset value as relatively attractive. Ford keeps her Neutral rating on Ventas shares however, forecasting the REIT to produce below-average FFO growth because of deleveraging activity.

TODAY'S FREE FLY STORIES

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

POAI

Predictive Oncology

$0.44

0.0101 (2.35%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BK

BNY Mellon

$45.34

0.975 (2.20%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
BNY Mellon SVP Harris sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
Breaking Hot Stocks news story on Foamix 

Foamix trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

BAC

Bank of America

$30.37

0.1 (0.33%)

16:35
10/18/19
10/18
16:35
10/18/19
16:35
Hot Stocks
Bank of America's Knox sells 40,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

LGC

Legacy Acquisition Corp

$10.24

0.02 (0.20%)

16:34
10/18/19
10/18
16:34
10/18/19
16:34
Conference/Events
Legacy Acquisition Corp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

16:33
10/18/19
10/18
16:33
10/18/19
16:33
Periodicals
OpenText weighing takeover bid for rival Micro Focus, Bloomberg says »

Open Text (OTEX) is…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

16:30
10/18/19
10/18
16:30
10/18/19
16:30
Options
Preliminary option volume of 21.9M today »

Preliminary option volume…

BA

Boeing

$344.01

-25.12 (-6.81%)

, ORCL

Oracle

$54.55

-0.52 (-0.94%)

16:22
10/18/19
10/18
16:22
10/18/19
16:22
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. earnings have…

BA

Boeing

$344.01

-25.12 (-6.81%)

ORCL

Oracle

$54.55

-0.52 (-0.94%)

KO

Coca-Cola

$54.78

0.98 (1.82%)

AXP

American Express

$116.82

-2.35 (-1.97%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

M

Macy's

$15.11

-0.66 (-4.19%)

LB

L Brands

$16.32

-1.78 (-9.83%)

GPS

Gap

$16.87

-0.71 (-4.04%)

LEVI

Levi Strauss

$17.12

0.07 (0.41%)

DERM

Dermira

$7.17

1.49 (26.23%)

ETFC

E-Trade

$40.82

1.78 (4.56%)

GIL

Gildan Activewear

$26.29

-9.085 (-25.68%)

TEAM

Atlassian

$116.96

-5.47 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 06

    Dec

  • 07

    Dec

EYEG

EyeGate

$3.40

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for October 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$20.36

0.36 (1.80%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Hot Stocks
Glenview Capital discloses 14.7% activist stake in Meritor »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BCBP

BCB Bancorp

$12.91

-0.04 (-0.31%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Earnings
BCB Bancorp reports Q3 EPS 30c, consensus 30c »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/18/19
10/18
16:16
10/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$5.35

0.12 (2.29%)

16:15
10/18/19
10/18
16:15
10/18/19
16:15
Syndicate
Breaking Syndicate news story on Universal Technical »

Universal Technical files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$246.37

2.62 (1.07%)

16:13
10/18/19
10/18
16:13
10/18/19
16:13
Hot Stocks
UnitedHealth's Burke sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:09
10/18/19
10/18
16:09
10/18/19
16:09
Hot Stocks
Foamix announces FDA approval of AMZEEQ topical foam, 4% »

Foamix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees Q3 net sales $325M, consensus $348.82M »

Michael F. Barry,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees FY19 pro forma adjusted EBITDA down 2%-4% »

Quaker Houghton updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.28

0.08 (0.22%)

16:04
10/18/19
10/18
16:04
10/18/19
16:04
Periodicals
GM to build new electric pickups, SUVs at Detrioit-Hamtramck plant, Reuters says »

Beginning in late 2021,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.